MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qai.0000000000003453

Медицинская библиотека · Journal of acquired immune deficiency syndromes (1999) · 2024

Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection.

Cyktor Joshua C, Yeh Eunice, Ribaudo Heather, Hoeth Dianna, Naqvi Asma, Bell Tanvir, Ridker Paul M, Fichtenbaum Carl, Daar Eric S, Havlir Diane, Tawakol Ahmed, Lederman Michael M, Stein James H, Deeks Steven G, Currier Judith S, Hsue Priscilla Y, Mellors John W, A5314 Team

СтатьяРандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование II фазыПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

People with HIV-1 often have chronic inflammation leading to severe non-AIDS morbidity and mortality. The AIDS Clinical Trials Group Study A5314 sought to lower inflammation with low-dose methotrexate (LDMTX). The primary study outcomes were reported previously but here we present the impact of LDMTX on multiple measures of HIV-1 persistence.

METHODS

A5314 was a phase 2 randomized, double-blind, multicenter trial in 176 adult people with HIV-1 on virally suppressive antiretroviral therapy. LDMTX (5-15 mg/wk) was administered for 24 weeks with an additional 12 weeks of participant follow-up. The current analyses of HIV-1 persistence were restricted to 60 participants (30 LDMTX and 30 placebo) randomly selected from the total population. Plasma HIV-1 RNA, total HIV-1 DNA, and cell-associated HIV-1 RNA (CA HIV-1 RNA) were measured by sensitive quantitative PCR assays.

RESULTS

LDMTX treatment had no significant effect on sensitive measures of plasma HIV-1 RNA, HIV-1 DNA, CA HIV-1 RNA, or CA HIV-1 RNA/DNA ratio at any time point or from baseline to week 24. As observed in the main study, absolute peripheral CD4+ and CD8+ T-cell numbers decreased from baseline to week 24 among the 30 participants receiving LDMTX compared with placebo (median decrease of -31.5 CD4+ T cells/µL, -83.5 CD8+ T cells/µL).

CONCLUSIONS

LDMTX had no significant effect on any measure of HIV-1 persistence in plasma or peripheral blood mononuclear cells. Further studies are needed to determine whether other immunosuppressive and/or immunoreductive interventions are safe and capable of affecting HIV-1 persistence.

Для цитирования: Cyktor Joshua C, Yeh Eunice, Ribaudo Heather, Hoeth Dianna, Naqvi Asma, Bell Tanvir, Ridker Paul M, Fichtenbaum Carl, Daar Eric S, Havlir Diane, Tawakol Ahmed, Lederman Michael M, Stein James H, Deeks Steven G, Currier Judith S, Hsue Priscilla Y, Mellors John W, A5314 Team. Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection.. Journal of acquired immune deficiency syndromes (1999). 2024. DOI: 10.1097/qai.0000000000003453.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.